PMID- 35151299
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220328
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Feb 12
TI  - The relation between serum uric acid levels and diabetic peripheral neuropathy in 
      type 2 diabetes in Guilan, north of Iran.
PG  - 39
LID - 10.1186/s12902-022-00952-5 [doi]
LID - 39
AB  - BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common 
      chronic microvascular complications in type 2 diabetes mellitus (T2DM). Hence, 
      the present study aimed to investigate the association between Serum Uric Acid 
      (SUA) levels and diabetic peripheral polyneuropathy in patients with type 2 
      diabetes. METHODS: We performed this case-control study during 2019-2020 on 
      individuals with diabetes referring to the Razi clinic of Rasht, in the north of 
      Iran. Polyneuropathy in patients was assessed based on the Neuropathy Disability 
      Score (NDS), Diabetic neuropathy symptom score (DNS) scoring system, and 
      electromyography (EMG)/nerve conduction velocity (NCV). The inclusion criterion 
      for the control group was normal EMG/NCV. Then, the patients were assessed for 
      SUA level and also laboratory results. RESULTS: In total, 230 patients with type 
      2 diabetes were examined. The mean SUA level in the DPN group was significantly 
      higher compared to the control group (6.72 +/- 1.75 vs. 4.57 +/- 1.49 mg/dL). With 
      increasing the SUA, the odds of developing neuropathy increased by 2.2 times 
      (OR = 2.2). The risk factors for diabetic polyneuropathy included gender (male) 
      (OR = 0.347), SBP (OR = 1.1), retinopathy (OR = 3.29), and microalbuminuria 
      (OR = 4.44). The chance of developing polyneuropathy in patients with retinopathy 
      was 3.3 times higher than in the control group, it was 4.4 times in 
      microalbuminuria patients. CONCLUSION: Elevated SUA level increased the chance of 
      developing peripheral polyneuropathy in a person with type 2 diabetes. SUA levels 
      higher than 5.25 mg / dL expose a person with type 2 diabetes to developing 
      peripheral polyneuropathy.
CI  - (c) 2022. The Author(s).
FAU - Fayazi, Haniye Sadat
AU  - Fayazi HS
AD  - Department of Internal Medicine, School of Medicine, Razi Hospital, Guilan 
      University of Medical Sciences, Rasht, Iran.
FAU - Yaseri, Maryam
AU  - Yaseri M
AD  - Department of Internal Medicine, School of Medicine, Razi Hospital, Guilan 
      University of Medical Sciences, Rasht, Iran. maryam.yaseri21@yahoo.com.
FAU - Mortazavi, Seyyede Sahere
AU  - Mortazavi SS
AD  - Department of Internal Medicine, School of Medicine, Razi Hospital, Guilan 
      University of Medical Sciences, Rasht, Iran.
FAU - Sharifhassan, Zahra
AU  - Sharifhassan Z
AD  - Razi Clinical Research Development Unit, Guilan University of Medical Sciences, 
      Rasht, Iran.
FAU - Assadinia, Ali-Sina
AU  - Assadinia AS
AD  - Razi Clinical Research Development Unit, Guilan University of Medical Sciences, 
      Rasht, Iran.
LA  - eng
PT  - Journal Article
DEP - 20220212
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Biomarkers)
RN  - 268B43MJ25 (Uric Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Diabetic Neuropathies/*blood
MH  - Female
MH  - Humans
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Uric Acid/*blood
PMC - PMC8840027
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Diabetic polyneuropathy
OT  - Type 2 diabetes
OT  - Uric acid
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/02/14 06:00
MHDA- 2022/03/29 06:00
PMCR- 2022/02/12
CRDT- 2022/02/13 20:24
PHST- 2021/04/02 00:00 [received]
PHST- 2022/02/03 00:00 [accepted]
PHST- 2022/02/13 20:24 [entrez]
PHST- 2022/02/14 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2022/02/12 00:00 [pmc-release]
AID - 10.1186/s12902-022-00952-5 [pii]
AID - 952 [pii]
AID - 10.1186/s12902-022-00952-5 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 Feb 12;22(1):39. doi: 10.1186/s12902-022-00952-5.